ARCHIMED
Also known as ARCHIMED SAS
Lyon- and New York-based private-equity firm focused solely on healthcare; small- and mid-cap growth buyouts of €10M–€1B through its MED fund series (MED IV closed at €1.5bn in 2026).
- HEADQUARTERS
- Lyon, France
- FOUNDED
- 2014
- AUM
- —
- OUTSIDE CAPITAL
- Yes
- TEAM LISTED
- 8 people
Focus
- STAGES
- GrowthBuyout
- ASSET MIX
- Private equity
- GEOGRAPHY
- GlobalEuropeNorth AmericaAsia-Pacific
Overview
ARCHIMED is a healthcare-only private-equity manager headquartered in Lyon and New York, authorised by the AMF (GP-14000002). It makes small- and mid-cap growth buyouts, buying from and partnering with families, founders, managers and corporates (including take-privates), investing €10M to €1B per company across seven healthcare sectors, from life-science tools and diagnostics to medtech, healthcare IT and animal health. Since 2014 it has raised the MED I–IV funds (small-cap to lower mid-cap) and the MED Platform I and II mid-cap funds, plus MED Rise, MED Bio and the evergreen MED Access. It reports more than 160 staff of over 35 nationalities.
Investment thesis
Healthcare specialisation via a proprietary segmentation of more than 450 sub-sectors; growth levers after investment include internationalisation, innovation, acquisitions and capacity expansion.
PORTFOLIO (12)
- StagoNOTABLEHealthTech · since 2026
- ZimVieNOTABLEHealthTech · since 2025
- NAMSANOTABLEHealthTech · since 2020
- Polyplus-transfectionNOTABLEBiotech & Life Sciences · since 2016 · Exited
- IRABHealthTech · since 2026
- Esperion TherapeuticsBiotech & Life Sciences · since 2026
- Ceva Animal HealthBiotech & Life Sciences · since 2025
- JeisysHealthTech · since 2024
- InstemSoftware & SaaS · since 2023
- Natus NeuroHealthTech · since 2022
- SuanfarmaBiotech & Life Sciences · since 2021
- ProlleniumHealthTech · since 2021
People
- Denis RibonChairman and Managing Partner · source
- Vincent GuillaumotManaging Partner · source
- André-Michel BallesterManaging Partner · source
- Sandrine LaporteFinance and Operations Partner · source
- Baptiste MélinonPartner, Head of Investor Relations · source
- Loïc KubitzaPartner · source
- Thibaut MongonPartner · source
- Angie KimManaging Director · source
Links
Frequently asked questions
ARCHIMED is a private equity fund based in Lyon, France, founded in 2014.
Yes. ARCHIMED invests its own capital in private companies.
ARCHIMED invests at Growth and Buyout stages in HealthTech and Biotech & Life Sciences.
ARCHIMED's stated ticket size is €10M–€1B.
Key people at ARCHIMED include Denis Ribon (Chairman and Managing Partner), Vincent Guillaumot (Managing Partner), André-Michel Ballester (Managing Partner) and Sandrine Laporte (Finance and Operations Partner).
ARCHIMED's investments include Stago, ZimVie, NAMSA, Polyplus-transfection, IRAB, Esperion Therapeutics, Ceva Animal Health and Jeisys, among others.
The most recent publicly reported investment by ARCHIMED is Esperion Therapeutics (Take-private), announced in Jul 2026.
Yes. ARCHIMED manages capital from outside investors.